Regenerative Medical Technology Company
Sign up today and learn more about Humacyte Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Humacyte Stock
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products called human acellular vessels (HAV) for regenerative medicine and vascular surgery applications. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Chief Executive Officer
Chief Financial Officer
Business Wire - Mar, 27 2020Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”
Business Wire - Mar, 2 2020Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering
Business Wire - Apr, 8 2019Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium
xconomy - Mar, 8 2019Humacyte Appoints Chris Fang Chief Medical Officer
xconomy - Jun, 25 2018Humacyte Promotes Jeffrey Lawson to Chief Executive
prnewswire - Jun, 11 2018Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investment
businesswire - Mar, 9 2018Humacyte Closes $75 Million Series C Financing
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase